Faes Farma S.A./€FAE

1D1W1MYTD1Y5YMAX

About Faes Farma S.A.

Faes Farma S.A. is a pharmaceutical company engaged in the research, production, and marketing of pharmaceutical products. Headquartered in Leioa, Spain, the company operates primarily in the pharmaceuticals and animal health sectors. Key products include prescription medications for human health, over-the-counter medicines, and nutritional supplements, as well as products for veterinary use. Founded in 1933, Faes Farma has expanded its operations to various international markets, particularly in Europe and Latin America. Its competitive strength lies in its robust R&D capabilities and a well-established distribution network.
Ticker
€FAE
Sector
Health
Primary listing
BME
Employees
2,611
Headquarters
Leioa, Spain
Website
faesfarma.com

Faes Farma S.A. Metrics

BasicAdvanced
€1.4B
17.46
€0.27
0.34
€0.10
2.21%

Bulls say / Bears say

Faes Farma delivered strong first-half momentum: revenue rose 27% to €391.5 million, EBITDA increased 24% to €90.8 million and net profit grew 9% to €57 million. It reaffirmed 2026 guidance for revenue growth of 17–19% and EBITDA growth of 28–31%. (Faes Farma)
The SIFI and Laboratório Edol acquisitions are giving Faes Farma a new ophthalmology growth platform, already contributing 16% of group revenue. International direct-sales revenue rose 83% in the first half, with Latin America a key driver, creating scope for further scale and diversification. (Faes Farma, Redacción Médica)
Faes Farma is broadening its product base beyond bilastine: Akantior received reimbursement approval in Italy, mesalazine 1,500 mg tablets secured European authorisation, and the company agreed to commercialise a urology treatment across 13 Latin American countries. These milestones could add new revenue streams as older products mature. (Faes Farma, Seoul Economic Daily)
Bilastine licensing revenue fell 9% in the first half because patent protection ended in Japan and competition intensified. Although other markets partly offset the decline, further generic pressure could weaken an important earnings contributor. (Faes Farma, Cinco Días)
The acquisitions are not yet translating fully into bottom-line growth: Faes Farma incurred €3.2 million of integration and restructuring costs, while net profit rose only 9% against 27% revenue growth. Further integration work and the move to the Derio plant could keep weighing on margins and earnings conversion. (Cinco Días, Faes Farma)
Acquisitions have increased financial risk: net debt stood at €261.4 million at the half-year, albeit below two times EBITDA. If cash generation or acquisition synergies disappoint, the enlarged debt load could restrict investment and leave less room for shareholder returns. (Cinco Días, Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.